Abstract:Abstract Background: Previous studies have demonstrated that proliferation- and ER-associated gene expression shows a time-dependent interaction with risk of recurrence. Breast Cancer Index (BCI) is a gene expression-based test that integrates biomarker panels of both proliferation (Molecular Grade Index, MGI), and endocrine response (HOXB13/IL17BR, H/I). BCI has been validated as a significant and independent prognostic factor both for risk of overall (0-10y) and late (>5y) distant recurrence and is predictive of extended endocrine benefit in patients with early-stage, hormone receptor-positive (HR+) breast cancer. In this study, correlative analyses were performed to evaluate molecular measures of proliferation and ER signaling by MGI and H/I that underly recurrence risk across clinical categories in patients receiving BCI testing as part of routine care. Methods: Analysis was performed using the BCI Clinical Database for Correlative Studies, an IRB-approved de-identified database which contains >50 data elements including clinicopathologic and molecular variables from 19,126 clinical cases submitted for BCI testing. Descriptive analyses assessed the distribution of MGI by H/I categories based on time of testing or BCI intervention point (time of diagnosis <1y for early recurrence vs 4-7y post diagnosis for late recurrence), lymph node status (N0 vs. N+), age (<50y vs. ≥50y), tumor size (T1-T3), and grade (1-3) to understand the molecular features that may be associated with recurrence in HR+ disease. Results: Analysis included 18,853 patients (88% ≥50y, 73% N0, 70% pT1, 51% grade 2). Comparative analysis of patients tested with BCI at <1y vs. those recurrence-free and tested at 4-7y post diagnosis showed a similar proportion of patients in the H/I categories (H/I-High: 44%1y, 43% 4-7y, P=0.510). An increased proportion of MGI-High was observed in 4-7y (61%) vs. 1y (53%) (P<0.001). The distribution of MGI categories within H/I-Low and High subsets was also similar based nodal status (N0 vs. N+), age (<50y vs. ≥50y), and tumor size. However, H/I status was inversely proportional to tumor grade (P<0.001): the proportion of H/I-Low decreased with increasing grade (Grade 1: 70%, 2: 59%, 3: 36%), whereas the proportion of H/I-High patients increased (Grade 1: 30%, 2: 41%, 3: 64%). In the H/I-Low subset, as grade increased, the proportion of MGI-Low patients decreased (1: 45%, 2: 23%, 3: 5%), while MGI-High remained relatively consistent across grade (1: 25%, 2: 36%, 3: 31%). In H/I-High patients, MGI-High increased as grade increased (1: 11%, 2: 26%, 3: 59%). Conclusion: BCI functional characterization using MGI for tumor proliferation and H/I for estrogen signaling in this large-scale analysis showed that over half (59%,1y vs. 67%, 4-7y) of endocrine responsive tumors (H/I-High) were also highly proliferative (MGI-High) irrespective of time of testing. Results showed that tumor grade correlated with MGI and H/I status, indicating that a subset of high-grade tumors were highly proliferative as well as endocrine responsive. These findings suggest that proliferation and endocrine signaling are combinatorial molecular drivers of recurrences in HR+ breast cancer. Table 1.Biomarker categorization by H/I and MGI status by time of testing, nodal status, age, tumor size, and grade.H/I-LowH/I-HighPatientsNMGI-Low (%)MGI-High (%)MGI-Low (%)MGI-High (%)Time of testing<1y1278282718264-7y1305725321429Nodal StatusN0950227311428N+344222311631Age<50y475824361129≥50y1409526301529Tumor SizeT1464930311524T2182619321435T319927311527Grade1224245251911239812336152631530531559 Citation Format: Reshma Mahtani, Yuan Yuan, Kari B Wisinski, Jay Morris, Max Salganik, Yi Zhang, Catherine A Schnabel, Vk Gadi. Breast cancer index and assessment of tumor proliferation by molecular grade index (MGI) within distinct HOXB13/IL17BR (H/I) subsets [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD9-09.

Expression of PGRMC1 in Paraffin-Embedded Tissues of Breast Cancer.

May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?

Abstract PD9-09: Breast cancer index and assessment of tumor proliferation by molecular grade index (MGI) within distinct HOXB13/IL17BR (H/I) subsets

Clinical Importance of PGRMC1 in Hormone Responsive Breast Cancer

Increased Expression of Progesterone Receptor Membrane Component 1 is Associated with Aggressive Phenotype and Poor Prognosis in ER-positive and Negative Breast Cancer.

Progress in research on possible role of progesterone receptor membrane component 1 (PGRMC1) in the mechanism of breast cancer development

Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers

Expression of Androgen Receptor in Breast Cancer and Its Prognostic Significance

Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics

TRPS1 Regulates the Opposite Effect of Progesterone Via RANKL in Endometrial Carcinoma and Breast Carcinoma

Comprehensive Analysis of the Implication of PGRMC1 in Triple-Negative Breast Cancer

Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis

Abstract 5364: Progesterone receptor modulates the antigen processing and presentation machinery decreasing MHC class I expression on tumors

Abstract P4-04-07: Progesterone promotes immunomodulation and tumor development in the murine mammary gland

Expression of polymeric immunoglobulin receptor (PIGR) and the effect of PIGR overexpression on breast cancer cells

Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer

Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma

PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth

GRP94 overexpression as an indicator of unfavorable outcomes in breast cancer patients

Abstract P5-10-11: Comparison of the Parallel Quantitative Expression Profiling in Paired FF and FFPE Samples with IHC4 by Using Two Prespecified Prognostic Models

Pleiotropic Actions of PGRMC Proteins in Cancer